Novocure’s virtual Research & Development Day on November 12 will highlight progress across clinical and developmental pipelines and introduce areas of focus in translational research ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will host a virtual Research & Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EDT on …

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today initiatives to bring attention to Mesothelioma Awareness Day on September 26. In partnership with the Mesothelioma Applied Research Foundation, Novocure has arranged for 25 buildings and landmarks to be lit in blue, the color associated with mesothelioma awareness. In 18 cities across the country including New York, …

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that William Doyle, the company’s Executive Chairman, and Dr. Uri Weinberg, the company’s Chief Science Officer, will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020. Mr. Doyle and Dr. Weinberg will take part in a fireside chat at 8:40 a.m. EDT. Mr. …

Wilco Groenhuysen appointed to an expanded Chief Operating Officer role Ashley Cordova promoted to Chief Financial Officer Frank Leonard promoted to Chief Development Officer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) today announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020, intended to further solidify executive leadership in preparation for an anticipated period of …

Quarterly net revenues of $115.9 million, representing 34 percent growth versus the second quarter 2019 and 14 percent growth versus the first quarter 2020 Financial strength allows for continued investments in clinical and product innovation ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2020, highlighting revenue growth …

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today the recipients of the AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort between Novocure and the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields. The AACR is the first and largest cancer research organization …

EF-33 will test the potential incremental survival benefit of Tumor Treating Fields delivered using high-intensity arrays in patients with recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with recurrent …

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating Fields together with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treatment of non-small cell lung cancer (NSCLC). Novocure’s Tumor Treating Fields use electric …

Optune Lua, formerly known as NovoTTF-100L, was approved by the FDA one year ago and is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe …

Final data collection will occur in six months ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. The final data collection date is six months after …